No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
N Engl J Med. 2021 Mar 11;384(10): 905-914.Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, serious adverse events, and grade 3 or 4 adverse events through day 5. Secondary outcomes of interest included the incidence of hospital discharge, incidence of infusion reaction, the composite safety outcome of organ dysfunction and serious co-infection, mortality, and pulmonary ordinal and pulmonary plus ordinal outcomes (measures of oxygen requirements and organ dysfunction, respectively). Outcomes were assessed for a median of 31 days follow up. Results revealed no statistically significant differences in all outcomes between the two groups (p>0.05 for all).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
